Cost-effectiveness analysis of rezivertinib and gefitinib in patients with EGFR-mutated advanced non-small cell lung cancer [0.03%]
瑞替普坦和吉非替尼治疗EGFR突变的晚期非小细胞肺癌的成本效益分析
Conghui Kou,Huina Wu,Lihui Liu et al.
Conghui Kou et al.
Background: Epidermal growth factor receptor (EGFR) mutations represent the primary driver alterations in advanced non-small cell lung cancer (NSCLC). Rezivertinib has emerged as a promising targeted therapy for EGFR-muta...
Real-world healthcare resource utilization and medical costs in patients with overweight or obesity and multimorbidity treated with semaglutide in the United States [0.03%]
在美国接受司美格鲁肽治疗的多病共存的超重或肥胖患者的真实世界医疗资源利用和医疗费用
Prachi Arora,Firas Dabbous,Sariya Udayachalerm et al.
Prachi Arora et al.
Background: Patients with overweight or obesity (OW/OB) are at increased risk for multimorbidity (≥2 obesity-related complications [ORCs]) and accompanying increases in mortality and excess costs. ...
Cost-effectiveness analysis of artificial intelligence (AI) for response prediction of neoadjuvant radio(chemo)therapy in locally advanced rectal cancer (LARC) in the Netherlands [0.03%]
人工智能预测新辅助放（化）疗后局部晚期直肠癌（LARC）反应的 cost-effectiveness 分析
L Maas,C Contreras-Meca,S Ghezzo et al.
L Maas et al.
Background: Given the potential of artificial intelligence (AI) and the increasing importance of understanding AI's economic impact, this study aims to provide insights into the potential cost-effectiveness of an AI tool ...
How do we approach integrating digital endpoint studies into Health technology assessment? [0.03%]
如何在卫生技术评估中纳入数字化终端研究？
Vijay Kumar Chattu,Anthony Scaffeo,Sujatha Alla et al.
Vijay Kumar Chattu et al.
Introduction: The integration of digital endpoints into Health Technology Assessment (HTA) marks a significant advancement in modern healthcare evaluation, especially in the context of post-pandemic growth in telehealth a...
Cost of rimegepant and lasmiditan associated adverse events, for acute treatment in migraine in Spain [0.03%]
西班牙急性治疗偏头痛的rimegepant和lasmiditan相关不良事件的成本
Sonia Santos Lasaosa,Beatriz Armada,Carlota Moya-Alarcón et al.
Sonia Santos Lasaosa et al.
Objective: To compare the cost of adverse events (AEs) associated with the acute treatment with rimegepant (RIM) versus lasmiditan (LAS) for migraine in Spain. ...
Cost-utility of pre-emptive plerixafor versus rescue plerixafor in the mobilization of hematopoietic stem cells in multiple myeloma [0.03%]
在多发性骨髓瘤中预防使用普乐西福动员造血干细胞的效用成本分析与补救使用相比
Tallys Feldens,Roselene Mesquita Augusto Passos,Juliana de Oliveira Martins et al.
Tallys Feldens et al.
Background: Multiple myeloma (MM) is a hematologic cancer withrising incidence worldwide. Autologous stem cell transplantation(ASCT) is a key treatment for eligible patients, but mobilizationfailure remains a major obstac...
The pharmaceutical market: a transdisciplinary description of concepts and their implications [0.03%]
药学市场：一种跨学科的概念描述及其影响
André Soares Motta-Santos,Kenya Valéria Micaela de Souza Noronha,Leonardo Costa Ribeiro et al.
André Soares Motta-Santos et al.
Introduction: The pharmaceutical industry has delivered innovative therapies that substantially improved health outcomes. However, concerns persist regarding high drug prices and delays in the entry of competitors. This a...
Cost-effectiveness of mechanical thrombectomy versus intravenous thrombolysis in acute ischemic stroke: a systematic review [0.03%]
急性缺血性卒中患者机械取栓与静脉溶栓治疗效果比较的系统综述
Nasim Jaberi,Mohammad Alimoradnori,Aghdas Souresrafil et al.
Nasim Jaberi et al.
Introduction: Mechanical thrombectomy (MT) is a proven treatment for acute ischemic stroke (AIS), yet its cost-effectiveness across global settings remains unclear. This systematic review synthesizes cost-effectiveness ev...
The role of patient-reported outcomes in health technology assessments: global practices and future implications [0.03%]
患者报告结果在卫生技术评估中的作用：全球实践及对未来的影响
Nenad Medic,James Ryan,Calvin N Ho et al.
Nenad Medic et al.
Background: Patient-reported outcome (PRO) data capture patients' perspectives on their disease and its treatments; however, use of such data in health technology assessments (HTA) and pricing/reimbursement processes is l...
Francisco Santos-Gonzalez,Ellenore Martin,Madeleine Harris et al.
Francisco Santos-Gonzalez et al.
Background: Functional genomics approaches, such as transcriptomics and proteomics, can provide valuable insights into rare diseases when genomic sequencing fails to yield informative findings. This study estimated the mo...